LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕
  • 07/07/2025

    EuropaBio Position on the Critical Medicines Act
  • 24/06/2025

    EuropaBio recommendations for the Bioeconomy Strategy
  • 24/06/2025

    Joint industry definitions of fermentation and precision fermentation
  • 18/06/2025

    EuropaBio conclusions on Patient BioForum 2025
  • 10/06/2025

    EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union
  • 04/06/2025

    EuropaBio response to EC Call for evidence for an evaluation of “Apply AI Strategy – strengthening the AI continent”
  • 16/04/2025

    EuropaBio position on the EU Life Sciences Strategy
  • 08/04/2025

    EFIB 2025 Brussels Statement
  • 24/03/2025

    Response to the EC Call for Evidence for an evaluation of ”EU rules on medical devices and in vitro diagnostics”
  • 18/03/2025

    Response to the European Commission Call for Evidence for the EU Startup and Scaleup Strategy
  • 07/03/2025

    Response to the Call for Evidence on the evaluation of the Public Procurement Directives
  • 26/02/2025

    EuropaBio response to the Call for Evidence on the Critical Medicines Act
  • 20/02/2025

    Implementation of the Net-Zero Industry Act
  • 09/02/2025

    Boosting Attractiveness of the EU for ATMP Developers
  • 31/01/2025

    EuropaBio Response to the Commission Public Consultation on the Single Market Strategy 2025
  • 20/01/2025

    The EU Biotech Act – EuropaBio Vision Paper
  • 05/12/2024

    Joint Industry Statement on JSC capacity
  • 19/07/2024

    Microorganisms & industrial biotechnology: challenges and opportunities for Europe
  • 18/07/2024

    EuropaBio Congratulates Ursula von der Leyen on Re-election as COM President
  • 04/07/2024

    Joint Statement for an Ambitious FP10
123...5
Next page
EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.